2022-06-172022-06-172022Al-Taie A, Arueyingho O, Khoshnaw J, Hafeez A. Clinical outcomes of multidimensional association of type 2 diabetes mellitus, COVID-19 and sarcopenia: an algorithm and scoping systematic evaluation. Arch Physiol Biochem. 2022 Jun 15:1-19. doi: 10.1080/13813455.2022.2086265. Epub ahead of print. PMID: 35704400.1381-3455http://doi.org/10.1080/13813455.2022.2086265https://hdl.handle.net/20.500.12713/2920Background: The aim of this study was to provide a scoping and comprehensive review for the clinical outcomes from the cross-link of Type 2 diabetes mellitus (T2DM), COVID-19, and sarcopenia. Methods: By using PRISMA guidelines and searching through different databases that could provide findings of evidence on the association of T2DM, COVID-19, and sarcopenia. Results: Thirty-three studies reported a relationship between sarcopenia with T2DM, twenty-one studies reported the prognosis COVID-19 in patients with T2DM, ten studies reported the prognosis of COVID-19 in patients with sarcopenia, five studies discussed the outcomes of sarcopenia in patients with COVID-19, and one study reported sarcopenia outcomes in the presence of T2DM and COVID-19. Conclusion: There is an obvious multidimensional relationship between T2DM, COVID-19 and sarcopenia which can cause prejudicial effects, poor prognosis, prolonged hospitalisation, lowered quality of life and a higher mortality rate during the current COVID-19 pandemic.eninfo:eu-repo/semantics/closedAccessCOVID-19Muscle MassSARS-CoV-2SarcopeniaType 2 Diabetes MellitusArticle35704400WOS:0008116606000012-s2.0-85131939470Q210.1080/13813455.2022.2086265Q2